Mock-ups: full-colour drafts of packaging and leaflet
Mock-ups are full-colour, actual-size drafts of the outer packaging, immediate packaging and leaflet that authorities review before a medicine is marketed.
The Notice to Applicants and EMA's procedural guidance distinguish a mock-up, a flat artwork copy of the pack and leaflet showing the final layout at actual size, from a specimen, which is a sample of the printed packaging as marketed. Mock-ups show how the particulars required by Articles 54, 55 and 59 of Directive 2001/83/EC, the Braille required by Article 56a and any national Blue Box content will actually appear, so that the authority can check legibility, the position of the safety features, the use of colour and the space left for variable data such as batch number and expiry date. The Commission's 2009 guideline on the readability of the labelling and package leaflet gives the design expectations the review applies, including a recommended minimum font size, line spacing and contrast.
In the centralised procedure, EMA asks for mock-ups of the outer and immediate packaging and the leaflet during the assessment, in time for the QRD review that precedes the CHMP opinion, and specimens of the final printed material are sent after the Commission decision. In mutual recognition and decentralised procedures the mock-ups belong to the national phase: each Member State sets whether it wants them, in which format and in which language, and they are submitted with the translations after the procedure closes. Later changes to artwork go through an Article 61(3) notification when they are not connected with the SmPC, and many authorities expect updated mock-ups with it. Some national authorities also review mock-ups for Blue Box content, which is outside the EU text.
What goes wrong: mock-ups are produced from a draft text and then not refreshed when the final product information changes in the last round of the procedure; the artwork is shown at reduced size so a 6-point leaflet looks fine on screen; the Braille is shown as a note rather than as dots in position; the 2D code and human-readable unique identifier are placed where the carton is folded; and national requirements are discovered market by market after the procedure has closed, which pushes launch dates. For multi-country packs, one Member State's objection can hold up every market that shares the artwork.
Timing
In the centralised procedure, mock-ups are submitted during the assessment in time for the QRD review before the CHMP opinion, and printed specimens follow once the Commission decision is adopted. In mutual recognition and decentralised procedures, mock-ups are submitted in the national phase together with the translations, where the CMDh timetable expects translated product information within days of the close of the procedure and the national authorisation within 30 days, so artwork has to be ready before the procedure ends. Updated mock-ups for later artwork changes are submitted with the Article 61(3) notification and are reviewed within its 90-day period.
Used in
Before mock-ups are submitted, compare each mock-up with the approved product information in Print Proofreader so the only differences are layout.
Related terms
- Labelling: text on the outer and immediate packagingLabelling is the information Articles 54 and 55 of Directive 2001/83/EC require on a medicine's outer and immediate packaging, from name to batch number.
- Package leaflet: patient information leaflet in the packThe package leaflet is the patient-facing text in every medicine pack, required by Articles 58 and 59 of Directive 2001/83/EC and based on the SmPC.
- Braille: product name in Braille on the outer packagingBraille on medicine packs is required by Article 56a of Directive 2001/83/EC: the name, and strength where needed, in Braille on the outer packaging.
- Article 61(3) notification: labelling or leaflet change outside the SmPCAn Article 61(3) notification tells the authority about a change to labelling or the package leaflet that does not affect the SmPC, with 90 days to object.
- DCP: decentralised procedureThe decentralised procedure (DCP) authorises a medicine in several EU/EEA Member States at once when it is not yet authorised in any of them.
Last updated